class = “sc-cffd1e67-0 fmXrkB”>
Among the 30 blue chips listed on SLI, VAT shares have emerged as the clear year-on-year winner, with current gains of around 64 percent. Like Logitech (+42%), they have benefited from the boom in tech-related stocks associated with the current “super topic” of artificial intelligence.
Logitech was followed on the podium by two financial stocks: Partners Group and UBS, each up a good 50 percent (as of December 19). UBS benefited, on the one hand, from the mass increase with the acquisition of CS, and on the other hand, from the confidence that the integration of CS would be successful. Of course, CS shareholders were left empty-handed afterwards.
Some cyclical stocks such as Holcim (+40%), ABB (+34%) and Kühne also benefited above average from the year-end rally in Swiss stocks, spurred by fantasies of rate cuts next year. +Nagel (+33%). All reached annual highs shortly before the end of the year.
Overall, the investor made double-digit profits for the year, outpacing inflation by a wide margin, with more than half of the 30 SLI shares held. Straumann, Sonova, Geberit, Swiss Life and Sika each rose by more than a fifth.
Investors had less luck in defensive heavyweights, which explains the less encouraging development of the overall market compared to international standards. While Novartis still gained 7 percent, holders of Nestlé (-10%) and Roche GS (-16%) suffered significant losses.
Roche investors are at a loss
Those who bet on Roche’s bearer shares had to distribute 27 percent of their investments. Roche I, together with Lonza (-23%), forms the bottom two among large Swiss stocks. Luxury goods stocks Swatch (-12%) and Richemont (-1%) lagged due to the sluggish economy in China.
As usual, second-ranked stocks experienced higher swings in both directions. For example, prices for two smaller healthcare companies more than doubled: Kuros Bioscience (+147%) and DocMorris (+162%). Dr. Morris recently received a boost from the upcoming approval of electronic prescriptions in Germany. However, the increase in DocMorris needs to be taken into account because over 500 francs had to be paid for the share in 2021. It’s currently just under 70 francs.
Those who bought One Swiss Bank’s shares at the 2022 closing price also almost doubled their shares. Here too the caveat that the previous year’s losses are only just being recouped applies.
Evolva, Igea Pharma and a Swiss bank, like the bankrupt Kinarus, are among those to be delisted soon. Due to the takeover of companies, Crealogix, Datacolor, Schaffner and Von Roll will soon disappear from the stock market.
Stock marketers were also unhappy with industrial stocks such as Meyer Burger (-64%), Aluflexpack (-52%) or OC Oerlikon (-37%). (SDA)
Source :Blick
I’m Tim David and I work as an author for 24 Instant News, covering the Market section. With a Bachelor’s Degree in Journalism, my mission is to provide accurate, timely and insightful news coverage that helps our readers stay informed about the latest trends in the market. My writing style is focused on making complex economic topics easy to understand for everyone.
